Canada Pension Plan Investment Board Takes Position in Sana Biotechnology, Inc. (NASDAQ:SANA)

Canada Pension Plan Investment Board bought a new position in Sana Biotechnology, Inc. (NASDAQ:SANA) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 10,175,000 shares of the company’s stock, valued at approximately $340,557,000. Canada Pension Plan Investment Board owned approximately 5.42% of Sana Biotechnology at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. Citigroup Inc. purchased a new position in Sana Biotechnology during the 1st quarter valued at about $79,000. UBS Group AG acquired a new position in shares of Sana Biotechnology in the first quarter worth $153,000. SG Americas Securities LLC purchased a new stake in shares of Sana Biotechnology during the first quarter worth $220,000. Rokos Capital Management LLP purchased a new position in Sana Biotechnology in the first quarter valued at about $243,000. Finally, Blue Pool Management Ltd. purchased a new position in Sana Biotechnology in the first quarter valued at about $251,000. Institutional investors and hedge funds own 47.35% of the company’s stock.

Shares of NASDAQ:SANA traded down $0.50 on Thursday, reaching $18.69. The company had a trading volume of 4,622 shares, compared to its average volume of 507,509. The company has a 50-day moving average of $20.41. Sana Biotechnology, Inc. has a twelve month low of $16.28 and a twelve month high of $44.60.

Sana Biotechnology (NASDAQ:SANA) last announced its earnings results on Wednesday, May 5th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.10). As a group, equities analysts forecast that Sana Biotechnology, Inc. will post -1.58 earnings per share for the current fiscal year.

Separately, Zacks Investment Research raised Sana Biotechnology from a “sell” rating to a “hold” rating in a research note on Thursday, July 8th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Sana Biotechnology currently has a consensus rating of “Hold” and an average target price of $40.00.

Sana Biotechnology Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops in vivo and ex vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others.

Further Reading: Average Daily Trade Volume Explained

Want to see what other hedge funds are holding SANA? Visit to get the latest 13F filings and insider trades for Sana Biotechnology, Inc. (NASDAQ:SANA).

Institutional Ownership by Quarter for Sana Biotechnology (NASDAQ:SANA)

Receive News & Ratings for Sana Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sana Biotechnology and related companies with's FREE daily email newsletter.